$ABBV (AbbVie Inc.) — investor discussion on X

Five-factor rating: Buy (sector percentile 68.1%)

Graded daily on value B-, growth A, profitability C-, momentum B, revisions B-. Sector-relative, identical for every user.

Most active credible voices on $ABBV

@schaeffers (Schaeffer's Investment Research) — 23 mentions · 14.7K followers
@wolfofharcourt (Wolf of Harcourt Street) — 19 mentions · 19.7K followers
@chitrader (CHItrader) — 16 mentions · 7.9K followers

Recent headlines featuring $ABBV

2026-09-22: Iambic files for U.S. IPO hours after AbbVie AI drug-discovery deal
2026-07-31: AbbVie posts $16.99 billion in Q2 revenue, trims full-year EPS guide to $13.87-$14.07

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $ABBV are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

For richer charts and full features, open SpikePanel on desktop.

$ABBV — what investors on X are saying · SpikePanel

$ABBVAbbVie Inc. · Drug Manufacturers - General · $521B

$296.01

post+0.3%

Event thread

Key events, in time order

30 items

2026-10-24 → 11-03EarningsBull
ABBV Raises Full-Year Guidance, Boosts Dividend 5.2%
Q3 beat expectations, raised 2026 revenue and EPS outlook, quarterly dividend up to $1.82
D1 +0.4% · +5d +0.7%
8 waves of this story
- 2026-10-24 Earnings approaching, focus on sustained growth
- 2026-10-25 Earnings schedule confirmed, with institutional buying and an individual exit plan adding to attention
- 2026-10-26 With earnings due Oct 30 pre-market, options pricing implies a roughly 5% move, drawing investor attention to results.
- 2026-10-27 Analysts expect immunology assets to drive beat, though rising costs and competition weigh
- 2026-10-30 Stock hits 52-week high on earnings day; focus on Skyrizi and Rinvoq growth
- 2026-10-30 Revenue and adj. EPS beat; immunology/neuroscience strength drives raised outlook
- 2026-10-31 Company raises revenue guidance; Skyrizi and Rinvoq combined growth $6B; adjusted EPS nearly doubled but includes last year's one-time charge
- 2026-11-03 Q3 beat expectations, raised 2026 revenue and EPS outlook, quarterly dividend up to $1.82
2026-11-038-K filing
8-K: Item 5.02
D1 -1.0% · +5d +2.8%

28 earlier events

2026-10-30Earnings
Earnings report
神经科学业务收入近34亿美元，运营增长19.5%；Vraylar全球销售额近11亿美元，增长14.3%。
D1 +1.4% · +5d -1.2%
2026-10-308-K filing
8-K: Item 2.02, Item 9.01
D1 +1.4% · +5d -1.2%
2026-10-27RegulationBull
ABBV Submits BLA to FDA for Etentamig in Relapsed/Refractory Multiple Myeloma
Second-gen BCMA bispecific T-cell engager with potential for broad community-based use, advancing oncology pipeline
D1 -0.1% · +5d -0.1%
2026-10-26CapitalBull
IRON Financial Raised ABBV Stake 122.4% in Q3
Institutional investor IRON Financial increased its ABBV position by 122.4% in Q3, reflecting institutional allocation moves.
D1 +0.4% · +5d +0.7%
2026-10-23ProductBull
FDA Approves Subcutaneous Skyrizi Induction for Crohn's Disease
New SC route expands Skyrizi's use, bolstering immunology pipeline
D1 +0.2% · +5d +3.2%
2026-10-22Capital
Axxcess Wealth Management Cuts ABBV Stake by 45.1% in Q3
SEC filing shows 45.1% Q3 reduction, signaling institutional repositioning
D1 +0.1% · +5d +2.0%
2026-10-22ProductBull
ABBV's Lutikizumab Meets Primary Endpoint in Phase 3 HS Trial
Phase 3 INTREPID met HiSCR75 primary and 8 secondary endpoints; company eyes weight-loss combination
D1 +0.1% · +5d +2.0%
2026-10-21Capital
Focused Alpha LLC Boosts AbbVie Stake by 109%
13F filing shows fund raised holdings to 4,657 shares, reflecting institutional capital movement
D1 -1.5% · +5d +0.4%
2026-10-21Company
AbbVie's Allergan Aesthetics to Present 8 Posters at AMWC Dubai
Long-term clinical evidence across HArmonyCa™ and other products strengthens multimodal aesthetic approach
D1 -1.5% · +5d +0.4%
2026-10-19 → 10-20ProductBull
ABBV Immunology Grows: Skyrizi & Rinvoq Revenue Up 24% Each
Total immunology revenue rose 15% in Q2, easing Humira loss concerns
D1 -1.0% · +5d +1.4%
2 waves of this story
- 2026-10-19 Company release: dual-targeting therapy beat anti-IL-23 or anti-α4β7 monotherapy at Week 12 primary endpoint
- 2026-10-20 Total immunology revenue rose 15% in Q2, easing Humira loss concerns
2026-10-20Company
ABBV Named Official Pharma Partner of McLaren F1 Team
Multi-year deal includes $10K donations to global charities for immunology community
D1 +2.3% · +5d -0.9%
2026-10-18Company
AbbVie to Present Seven Oncology Assets Data at 2026 ESMO Congress
Company release: new/updated data across seven assets in lung, colorectal, ovarian, prostate, gastric cancers
D1 -1.0% · +5d +1.4%
2026-10-17Capital
Institutional Trim vs. Dividend Growth: Mixed Signals for ABBV
Pictet cuts stake 8.3% while dividend keeps rising; top drugs cover payout
D1 -1.0% · +5d +1.4%
2026-10-168-K filing
8-K: Item 5.02
D1 +0.7% · +5d +0.1%
2026-10-16Other
ABBV Hits All-Time Highs as Defensive Flows Persist
Multiple independent sources confirm ABBV at 52-week and all-time highs amid defensive sector strength
D1 +0.7% · +5d +0.1%
2026-10-15Company
ABBV Shares Pull Back 2.4% After Recent 52-Week High
Price fluctuates near top of 52-week range; multiple sources note relative strength
D1 +0.0% · +5d +0.6%
2026-10-13Other
ABBV Hits New 52-Week High, Closes at $281.04
Multiple sources confirm new high; market eyes dividend yield and pipeline
D1 -2.4% · +5d +5.4%
2 waves of this story
- 2026-10-13 Multiple sources confirm ABBV's intraday all-time high, reflecting market recognition of recent fundamental progress
- 2026-10-13 Multiple sources confirm new high; market eyes dividend yield and pipeline
2026-10-09Capital
Institutional Moves: Bell Cuts ABBV Stake 48%, GAMMA Raises 10%
Two institutions took opposite actions in latest 13F filings, showing divergent views on ABBV.
D1 +1.5% · +5d +3.2%
2026-10-08 → 10-09AnalystBull
Cantor Fitzgerald Raises Price Targets on ABBV and Three Other Pharma Giants
Cantor lifts ABBV price target but notes mixed growth outlooks, with varying conviction across the four pharma names.
D1 +0.4% · +5d +4.0%
2 waves of this story
- 2026-10-08 Cantor raises ABBV price target from $285 to $290
- 2026-10-09 Cantor lifts ABBV price target but notes mixed growth outlooks, with varying conviction across the four pharma names.
2026-10-07 → 10-08ProductBull
ABBV's Temab-A Wins Two FDA Breakthrough Therapy Designations
FDA grants Breakthrough Therapy designations for colorectal cancer and NSCLC
D1 +1.8% · +5d +4.5%
2 waves of this story
- 2026-10-07 Temab-A granted BTDs for CRC and NSCLC
- 2026-10-08 FDA grants Breakthrough Therapy designations for colorectal cancer and NSCLC
2026-10-06Earnings
ABBV Issues Q3 2026 EPS Guidance of $3.73-$3.77
Company updated guidance Tuesday morning, range compared to consensus
D1 +0.3% · +5d +2.9%
2026-10-06ProductBull
ABBV Combo Shows PFS Benefit in Frontline DLBCL
Epcoritamab plus R-CHOP cut progression/death risk by 51%, meeting phase III PFS goal
D1 +0.3% · +5d +2.9%
2 waves of this story
- 2026-10-06 Epcoritamab plus R-CHOP significantly reduces risk of progression or death in frontline DLBCL in Phase 3
- 2026-10-06 Epcoritamab plus R-CHOP cut progression/death risk by 51%, meeting phase III PFS goal
2026-10-068-K filing
8-K: Item 2.02, Item 9.01
D1 +0.3% · +5d +2.9%
2026-10-02Company
AbbVie Joins US Pilot for Drug Discount Rebates
Participation in federal rebate pilot may shape future drug pricing
D1 +1.1% · +5d +5.2%
2026-09-25 → 10-02RegulationBull
ABBV's Juvmo Launch Targets October 2026 After FDA Approval
Commercial launch on track for Oct 2026, expanding neuroscience franchise
D1 -0.3% · +5d -0.6%
4 waves of this story
- 2026-09-25 FDA website shows approval, adding new growth driver to AbbVie's portfolio
- 2026-09-28 FDA approval of JUVMO, a selective D1/D5 agonist, with analyst projecting billion-dollar sales potential
- 2026-09-29 FDA approves once-daily oral Juvmo for Parkinson's; analysts see $5B+ potential
- 2026-10-02 Commercial launch on track for Oct 2026, expanding neuroscience franchise
2026-10-01Earnings
ABBV to Report Q3 2026 Earnings on Oct 30 Before Market Open
Company confirms Q3 results date; market watches growth drug performance
D1 -0.6% · +5d +4.8%
2026-09-29Company
ABBV Joins AI and Antibody Consortia, Deepening Tech Partnerships
Partners with Valkai for AI in clinical development; founding member of Antibody Developability Consortium
D1 -1.1% · +5d +1.3%
2026-09-22RegulationBull
ABBV's RINVOQ Wins EU Approval for Juvenile Idiopathic Arthritis
EU approval expands label to pJIA patients aged 2+, bolstering immunology pipeline
D1 +0.3% · +5d -0.7%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

30 items

2026-10-24 → 11-03EarningsBull
ABBV Raises Full-Year Guidance, Boosts Dividend 5.2%
Q3 beat expectations, raised 2026 revenue and EPS outlook, quarterly dividend up to $1.82
D1 +0.4% · +5d +0.7%
8 waves of this story
- 2026-10-24 Earnings approaching, focus on sustained growth
- 2026-10-25 Earnings schedule confirmed, with institutional buying and an individual exit plan adding to attention
- 2026-10-26 With earnings due Oct 30 pre-market, options pricing implies a roughly 5% move, drawing investor attention to results.
- 2026-10-27 Analysts expect immunology assets to drive beat, though rising costs and competition weigh
- 2026-10-30 Stock hits 52-week high on earnings day; focus on Skyrizi and Rinvoq growth
- 2026-10-30 Revenue and adj. EPS beat; immunology/neuroscience strength drives raised outlook
- 2026-10-31 Company raises revenue guidance; Skyrizi and Rinvoq combined growth $6B; adjusted EPS nearly doubled but includes last year's one-time charge
- 2026-11-03 Q3 beat expectations, raised 2026 revenue and EPS outlook, quarterly dividend up to $1.82
2026-11-038-K filing
8-K: Item 5.02
D1 -1.0% · +5d +2.8%
2026-10-30Earnings
Earnings report
神经科学业务收入近34亿美元，运营增长19.5%；Vraylar全球销售额近11亿美元，增长14.3%。
D1 +1.4% · +5d -1.2%
2026-10-308-K filing
8-K: Item 2.02, Item 9.01
D1 +1.4% · +5d -1.2%
2026-10-27RegulationBull
ABBV Submits BLA to FDA for Etentamig in Relapsed/Refractory Multiple Myeloma
Second-gen BCMA bispecific T-cell engager with potential for broad community-based use, advancing oncology pipeline
D1 -0.1% · +5d -0.1%

25 earlier events

2026-10-26CapitalBull
IRON Financial Raised ABBV Stake 122.4% in Q3
Institutional investor IRON Financial increased its ABBV position by 122.4% in Q3, reflecting institutional allocation moves.
D1 +0.4% · +5d +0.7%
2026-10-23ProductBull
FDA Approves Subcutaneous Skyrizi Induction for Crohn's Disease
New SC route expands Skyrizi's use, bolstering immunology pipeline
D1 +0.2% · +5d +3.2%
2026-10-22Capital
Axxcess Wealth Management Cuts ABBV Stake by 45.1% in Q3
SEC filing shows 45.1% Q3 reduction, signaling institutional repositioning
D1 +0.1% · +5d +2.0%
2026-10-22ProductBull
ABBV's Lutikizumab Meets Primary Endpoint in Phase 3 HS Trial
Phase 3 INTREPID met HiSCR75 primary and 8 secondary endpoints; company eyes weight-loss combination
D1 +0.1% · +5d +2.0%
2026-10-21Capital
Focused Alpha LLC Boosts AbbVie Stake by 109%
13F filing shows fund raised holdings to 4,657 shares, reflecting institutional capital movement
D1 -1.5% · +5d +0.4%
2026-10-21Company
AbbVie's Allergan Aesthetics to Present 8 Posters at AMWC Dubai
Long-term clinical evidence across HArmonyCa™ and other products strengthens multimodal aesthetic approach
D1 -1.5% · +5d +0.4%
2026-10-19 → 10-20ProductBull
ABBV Immunology Grows: Skyrizi & Rinvoq Revenue Up 24% Each
Total immunology revenue rose 15% in Q2, easing Humira loss concerns
D1 -1.0% · +5d +1.4%
2 waves of this story
- 2026-10-19 Company release: dual-targeting therapy beat anti-IL-23 or anti-α4β7 monotherapy at Week 12 primary endpoint
- 2026-10-20 Total immunology revenue rose 15% in Q2, easing Humira loss concerns
2026-10-20Company
ABBV Named Official Pharma Partner of McLaren F1 Team
Multi-year deal includes $10K donations to global charities for immunology community
D1 +2.3% · +5d -0.9%
2026-10-18Company
AbbVie to Present Seven Oncology Assets Data at 2026 ESMO Congress
Company release: new/updated data across seven assets in lung, colorectal, ovarian, prostate, gastric cancers
D1 -1.0% · +5d +1.4%
2026-10-17Capital
Institutional Trim vs. Dividend Growth: Mixed Signals for ABBV
Pictet cuts stake 8.3% while dividend keeps rising; top drugs cover payout
D1 -1.0% · +5d +1.4%
2026-10-168-K filing
8-K: Item 5.02
D1 +0.7% · +5d +0.1%
2026-10-16Other
ABBV Hits All-Time Highs as Defensive Flows Persist
Multiple independent sources confirm ABBV at 52-week and all-time highs amid defensive sector strength
D1 +0.7% · +5d +0.1%
2026-10-15Company
ABBV Shares Pull Back 2.4% After Recent 52-Week High
Price fluctuates near top of 52-week range; multiple sources note relative strength
D1 +0.0% · +5d +0.6%
2026-10-13Other
ABBV Hits New 52-Week High, Closes at $281.04
Multiple sources confirm new high; market eyes dividend yield and pipeline
D1 -2.4% · +5d +5.4%
2 waves of this story
- 2026-10-13 Multiple sources confirm ABBV's intraday all-time high, reflecting market recognition of recent fundamental progress
- 2026-10-13 Multiple sources confirm new high; market eyes dividend yield and pipeline
2026-10-09Capital
Institutional Moves: Bell Cuts ABBV Stake 48%, GAMMA Raises 10%
Two institutions took opposite actions in latest 13F filings, showing divergent views on ABBV.
D1 +1.5% · +5d +3.2%
2026-10-08 → 10-09AnalystBull
Cantor Fitzgerald Raises Price Targets on ABBV and Three Other Pharma Giants
Cantor lifts ABBV price target but notes mixed growth outlooks, with varying conviction across the four pharma names.
D1 +0.4% · +5d +4.0%
2 waves of this story
- 2026-10-08 Cantor raises ABBV price target from $285 to $290
- 2026-10-09 Cantor lifts ABBV price target but notes mixed growth outlooks, with varying conviction across the four pharma names.
2026-10-07 → 10-08ProductBull
ABBV's Temab-A Wins Two FDA Breakthrough Therapy Designations
FDA grants Breakthrough Therapy designations for colorectal cancer and NSCLC
D1 +1.8% · +5d +4.5%
2 waves of this story
- 2026-10-07 Temab-A granted BTDs for CRC and NSCLC
- 2026-10-08 FDA grants Breakthrough Therapy designations for colorectal cancer and NSCLC
2026-10-06Earnings
ABBV Issues Q3 2026 EPS Guidance of $3.73-$3.77
Company updated guidance Tuesday morning, range compared to consensus
D1 +0.3% · +5d +2.9%
2026-10-06ProductBull
ABBV Combo Shows PFS Benefit in Frontline DLBCL
Epcoritamab plus R-CHOP cut progression/death risk by 51%, meeting phase III PFS goal
D1 +0.3% · +5d +2.9%
2 waves of this story
- 2026-10-06 Epcoritamab plus R-CHOP significantly reduces risk of progression or death in frontline DLBCL in Phase 3
- 2026-10-06 Epcoritamab plus R-CHOP cut progression/death risk by 51%, meeting phase III PFS goal
2026-10-068-K filing
8-K: Item 2.02, Item 9.01
D1 +0.3% · +5d +2.9%
2026-10-02Company
AbbVie Joins US Pilot for Drug Discount Rebates
Participation in federal rebate pilot may shape future drug pricing
D1 +1.1% · +5d +5.2%
2026-09-25 → 10-02RegulationBull
ABBV's Juvmo Launch Targets October 2026 After FDA Approval
Commercial launch on track for Oct 2026, expanding neuroscience franchise
D1 -0.3% · +5d -0.6%
4 waves of this story
- 2026-09-25 FDA website shows approval, adding new growth driver to AbbVie's portfolio
- 2026-09-28 FDA approval of JUVMO, a selective D1/D5 agonist, with analyst projecting billion-dollar sales potential
- 2026-09-29 FDA approves once-daily oral Juvmo for Parkinson's; analysts see $5B+ potential
- 2026-10-02 Commercial launch on track for Oct 2026, expanding neuroscience franchise
2026-10-01Earnings
ABBV to Report Q3 2026 Earnings on Oct 30 Before Market Open
Company confirms Q3 results date; market watches growth drug performance
D1 -0.6% · +5d +4.8%
2026-09-29Company
ABBV Joins AI and Antibody Consortia, Deepening Tech Partnerships
Partners with Valkai for AI in clinical development; founding member of Antibody Developability Consortium
D1 -1.1% · +5d +1.3%
2026-09-22RegulationBull
ABBV's RINVOQ Wins EU Approval for Juvenile Idiopathic Arthritis
EU approval expands label to pJIA patients aged 2+, bolstering immunology pipeline
D1 +0.3% · +5d -0.7%

$ABBV (AbbVie Inc.) — investor discussion on X

Five-factor rating: Buy (sector percentile 68.1%)

Most active credible voices on $ABBV

Recent headlines featuring $ABBV

$ABBV (AbbVie Inc.) — investor discussion on X

Five-factor rating: Buy (sector percentile 68.1%)

Most active credible voices on $ABBV

Recent headlines featuring $ABBV

ABBV Raises Full-Year Guidance, Boosts Dividend 5.2%

8-K: Item 5.02

Earnings report

8-K: Item 2.02, Item 9.01

ABBV Submits BLA to FDA for Etentamig in Relapsed/Refractory Multiple Myeloma

IRON Financial Raised ABBV Stake 122.4% in Q3

FDA Approves Subcutaneous Skyrizi Induction for Crohn's Disease

Axxcess Wealth Management Cuts ABBV Stake by 45.1% in Q3

ABBV's Lutikizumab Meets Primary Endpoint in Phase 3 HS Trial

Focused Alpha LLC Boosts AbbVie Stake by 109%

AbbVie's Allergan Aesthetics to Present 8 Posters at AMWC Dubai

ABBV Immunology Grows: Skyrizi & Rinvoq Revenue Up 24% Each

ABBV Named Official Pharma Partner of McLaren F1 Team

AbbVie to Present Seven Oncology Assets Data at 2026 ESMO Congress

Institutional Trim vs. Dividend Growth: Mixed Signals for ABBV

8-K: Item 5.02

ABBV Hits All-Time Highs as Defensive Flows Persist

ABBV Shares Pull Back 2.4% After Recent 52-Week High

ABBV Hits New 52-Week High, Closes at $281.04

Institutional Moves: Bell Cuts ABBV Stake 48%, GAMMA Raises 10%

Cantor Fitzgerald Raises Price Targets on ABBV and Three Other Pharma Giants

ABBV's Temab-A Wins Two FDA Breakthrough Therapy Designations

ABBV Issues Q3 2026 EPS Guidance of $3.73-$3.77

ABBV Combo Shows PFS Benefit in Frontline DLBCL

8-K: Item 2.02, Item 9.01

AbbVie Joins US Pilot for Drug Discount Rebates

ABBV's Juvmo Launch Targets October 2026 After FDA Approval

ABBV to Report Q3 2026 Earnings on Oct 30 Before Market Open

ABBV Joins AI and Antibody Consortia, Deepening Tech Partnerships

ABBV's RINVOQ Wins EU Approval for Juvenile Idiopathic Arthritis

Bull vs bear

Discussion

ABBV Raises Full-Year Guidance, Boosts Dividend 5.2%

8-K: Item 5.02

Earnings report

8-K: Item 2.02, Item 9.01

ABBV Submits BLA to FDA for Etentamig in Relapsed/Refractory Multiple Myeloma

IRON Financial Raised ABBV Stake 122.4% in Q3

FDA Approves Subcutaneous Skyrizi Induction for Crohn's Disease

Axxcess Wealth Management Cuts ABBV Stake by 45.1% in Q3

ABBV's Lutikizumab Meets Primary Endpoint in Phase 3 HS Trial

Focused Alpha LLC Boosts AbbVie Stake by 109%

AbbVie's Allergan Aesthetics to Present 8 Posters at AMWC Dubai

ABBV Immunology Grows: Skyrizi & Rinvoq Revenue Up 24% Each

ABBV Named Official Pharma Partner of McLaren F1 Team

AbbVie to Present Seven Oncology Assets Data at 2026 ESMO Congress

Institutional Trim vs. Dividend Growth: Mixed Signals for ABBV

8-K: Item 5.02

ABBV Hits All-Time Highs as Defensive Flows Persist

ABBV Shares Pull Back 2.4% After Recent 52-Week High

ABBV Hits New 52-Week High, Closes at $281.04

Institutional Moves: Bell Cuts ABBV Stake 48%, GAMMA Raises 10%

Cantor Fitzgerald Raises Price Targets on ABBV and Three Other Pharma Giants

ABBV's Temab-A Wins Two FDA Breakthrough Therapy Designations

ABBV Issues Q3 2026 EPS Guidance of $3.73-$3.77

ABBV Combo Shows PFS Benefit in Frontline DLBCL

8-K: Item 2.02, Item 9.01

AbbVie Joins US Pilot for Drug Discount Rebates

ABBV's Juvmo Launch Targets October 2026 After FDA Approval

ABBV to Report Q3 2026 Earnings on Oct 30 Before Market Open

ABBV Joins AI and Antibody Consortia, Deepening Tech Partnerships

ABBV's RINVOQ Wins EU Approval for Juvenile Idiopathic Arthritis